GlassScriptPhysician profile
Tracie A Caller
NPI 1164645206
$2,091.46
in general payments reported to CMS, 2019-2025
23 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $285 · 2021: $490 · 2022: $12.16 · 2023: $73.86 · 2024: $557 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.22 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $315.70 | 2020-2021 | |
| Abbvie INC. | $281.67 | 2024-2025 | |
| Abbott Laboratories | $230.59 | 2020-2024 | Infinity |
| Medtronic USA, INC. | $224.31 | 2019-2020 | |
| Medtronic, INC. | $185.87 | 2021 | |
| Boston Scientific Corporation | $117.31 | 2024-2025 | Watchman |
| Novartis Pharmaceuticals Corporation | $116.17 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $90.00 | 2024 | |
| Biogen, INC. | $87.29 | 2021-2024 | Vumerity, Tysabri |
| Allergan, INC. | $76.63 | 2020-2021 | |
| Genentech USA, INC. | $53.29 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $43.95 | 2024 | Briviact |
| Argenx US, INC. | $42.92 | 2025 | Vyvgart |
| Tg Therapeutics, INC. | $42.23 | 2025 | |
| Ge Healthcare | $29.64 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $26.59 | 2025 | Gamunex-C |
| Celgene Corporation | $25.70 | 2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $21.61 | 2023 | Ultomiris |
| Genzyme Corporation | $21.12 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.69 | 2019 | |
| Pfizer INC. | $15.10 | 2025 | |
| International Rehabilitative Sciences, INC | $14.92 | 2025 | Rs-4i Plus With Intersperse |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie Caller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.